Research programme: bone regeneration therapies - AdociaAlternative Names: BioChaperone® BMP-2; BioChaperone® BMP-7; BioChaperone® BMPs
Latest Information Update: 22 Jan 2015
At a glance
- Originator Adocia
- Class Growth factors
- Mechanism of Action Bone morphogenetic protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Fracture; Osteoporosis; Spondylosis
Most Recent Events
- 22 Jan 2015 Discontinued - Preclinical for Fracture, Osteoporosis and Spondylosis in France (unspecified route)